'''Ciprefadol''' is an [[opioid]] [[analgesic]] that is an isoquinoline derivative most closely related to [[cyclazocine]] and [[picenadol]],<ref>[http://www.google.com/patents?id=XMUsAAAAEBAJ Dennis M. Zimmerman et al. N-cycloalkylmethyl decahydroisoquinolines. US Patent 4001248, Jun 7, 1974]</ref> with a number of other related compounds known.<ref>[http://www.google.com/patents?id=W_QsAAAAEBAJ David R. Brittelli et al. 4a-Aryl-trans-decahydroisoquinolines. US Patent 4419517, Apr 8, 1975]</ref><ref>[http://www.google.com/patents?id=OOQrAAAAEBAJ Henry Rapoport et al. Synthesis of 4A-aryl-decahydroisoquinolines. US Patent 4189583, Apr 26, 1978]</ref><ref>Judd DB, Brown DS, Lloyd JE, McElroy AB, Scopes DI, Birch PJ, Hayes AG, Sheehan MJ. Synthesis, antinociceptive activity, and opioid receptor profiles of substituted trans-3-(decahydro- and octahydro-4a-isoquinolinyl)phenols. ''Journal of Medicinal Chemistry''. 1992 Jan;35(1):48-56. {{PMID|1310115}}</ref><ref>Carroll FI, Chaudhari S, Thomas JB, Mascarella SW, Gigstad KM, Deschamps J, Navarro HA. N-substituted cis-4a-(3-hydroxyphenyl)-8a-methyloctahydroisoquinolines are opioid receptor pure antagonists. ''Journal of Medicinal Chemistry''. 2005 Dec 29;48(26):8182-93. {{PMID|16366600}}</ref> Ciprefadol is a mixed [[agonist–antagonist]] at μ-opioid receptors and can partly block the effects of morphine at low doses, though at higher doses it acts more like a full agonist. It is also a potent κ-opioid agonist, unlike the corresponding N-methyl and N-phenethyl derivatives which are reasonably μ-selective agonists.<ref>Zimmerman DM, Cantrell BE, Swartzendruber JK, Jones ND, Mendelsohn LG, Leander JD, Nickander RC. Synthesis and analgesic properties of N-substituted trans-4a-aryldecahydroisoquinolines. ''Journal of Medicinal Chemistry''. 1988 Mar;31(3):555-60. {{PMID|2831363}}</ref>
